Product Pipeline

We are advancing development of our lead candidate, partial MOR agonist EPD-2520, to first-in-human clinical trials.

EPD-2520 Pipeline

Our upcoming Phase 1 clinical trials for the pain indications and Opioid Use Disorder (OUD) are a single study, designed to provide clinical proof of concept of the key risks for an opioid:

  • Respiratory depression
  • Analgesia
  • Addictive liability in a study in recreational opioid users